9月2日，Twist Bioscience盘中上涨5.15%，报138.86美元/股，成交额2112.25万美元。该股早盘一度下挫近5%后快速反弹。
消息面上，Anthropic此前公布基于Claude大模型的蛋白质设计成果，在几乎无人工干预的条件下自主设计出14个临床靶点的蛋白结合剂，整体命中率达22.6%至35.1%，远超行业水平。Twist Bioscience作为独立实验验证平台之一，负责大规模快速合成AI设计蛋白并完成结合能力测试，该消息此前已推动股价单日大涨逾17%。此外，公司Q4营收指引1.23亿至1.24亿美元，显著高于市场预期的1.17亿美元，基本面支撑仍在。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.